﻿<?xml version="1.0" encoding="UTF-8"?>
<!--RSS generated by Windows SharePoint Services V3 RSS Generator on 21/05/2013 19:32:23-->
<?xml-stylesheet type="text/xsl" href="/_layouts/RssXslt.aspx?List=8bbf17cc-e1b7-4069-9190-15d260c24085" version="1.0"?>
<rss version="2.0">
  <channel>
    <title>Pharmamar: Noticias</title>
    <link>http://s16117373:11111/Lists/Noticias/vista aos friendly.aspx</link>
    <description>Fuente RSS para la lista Noticias.</description>
    <lastBuildDate>Tue, 21 May 2013 17:32:23 GMT</lastBuildDate>
    <generator>Windows SharePoint Services V3 RSS Generator</generator>
    <ttl>60</ttl>
    <image>
      <title>Pharmamar: Noticias</title>
      <url>/_layouts/images/homepage.gif</url>
      <link>http://s16117373:11111/Lists/Noticias/vista aos friendly.aspx</link>
    </image>
    <item>
      <title>20/05/2013</title>
      <link>http://s16117373:11111/Lists/Noticias/DispForm.aspx?ID=435</link>
      <description><![CDATA[<div><b>Fecha:</b> 20/05/2013</div>
<div><b>Enlace:</b> PharmaMar commences a Phase Ib trial with PM01183 in combination with Capecitabine</div>
<div><b>Noticia:</b> <div class=ExternalClass9E27D6E70E6D4530A59AF2E00745FD63><div></div></div></div>
<div><b>Datos adjuntos:</b> <a href="http://s16117373:11111/Lists/Noticias/Attachments/435/PM01183_Capecitabina_FI_en.pdf">http://s16117373:11111/Lists/Noticias/Attachments/435/PM01183_Capecitabina_FI_en.pdf</a><br><a href=""></a></div>
]]></description>
      <author>S16117373\pharmamar</author>
      <pubDate>Tue, 21 May 2013 10:41:02 GMT</pubDate>
      <guid isPermaLink="true">http://s16117373:11111/Lists/Noticias/DispForm.aspx?ID=435</guid>
    </item>
    <item>
      <title>20/05/2013</title>
      <link>http://s16117373:11111/Lists/Noticias/DispForm.aspx?ID=434</link>
      <description><![CDATA[<div><b>Fecha:</b> 20/05/2013</div>
<div><b>Enlace:</b> PharmaMar comienza el estudio de Fase Ib con PM01183 en combinación con capecitabina</div>
<div><b>Noticia:</b> <div class=ExternalClass0FEEB66E14254DB9A78D44747E6FEDC4>
<div></div></div></div>
<div><b>Datos adjuntos:</b> <a href="http://s16117373:11111/Lists/Noticias/Attachments/434/PM01183_Capecitabina_FI.pdf">http://s16117373:11111/Lists/Noticias/Attachments/434/PM01183_Capecitabina_FI.pdf</a><br><a href=""></a></div>
]]></description>
      <author>S16117373\pharmamar</author>
      <pubDate>Tue, 21 May 2013 10:28:56 GMT</pubDate>
      <guid isPermaLink="true">http://s16117373:11111/Lists/Noticias/DispForm.aspx?ID=434</guid>
    </item>
    <item>
      <title>16/05/2013</title>
      <link>http://s16117373:11111/Lists/Noticias/DispForm.aspx?ID=433</link>
      <description><![CDATA[<div><b>Fecha:</b> 16/05/2013</div>
<div><b>Enlace:</b> PharmaMar to present new studies with Yondelis® at ASCO</div>
<div><b>Noticia:</b> <div class=ExternalClassE81E8B9936C14FA0A058B4C222C05EEE><div></div></div></div>
<div><b>Datos adjuntos:</b> <a href="http://s16117373:11111/Lists/Noticias/Attachments/433/NdP PharmaMar_ASCO_2013_cast_en_final.pdf">http://s16117373:11111/Lists/Noticias/Attachments/433/NdP PharmaMar_ASCO_2013_cast_en_final.pdf</a><br><a href=""></a></div>
]]></description>
      <author>S16117373\pharmamar</author>
      <pubDate>Thu, 16 May 2013 12:31:35 GMT</pubDate>
      <guid isPermaLink="true">http://s16117373:11111/Lists/Noticias/DispForm.aspx?ID=433</guid>
    </item>
    <item>
      <title>16/05/2013</title>
      <link>http://s16117373:11111/Lists/Noticias/DispForm.aspx?ID=432</link>
      <description><![CDATA[<div><b>Fecha:</b> 16/05/2013</div>
<div><b>Enlace:</b> NUEVOS ESTUDIOS CON YONDELIS® SERÁN PRESENTADOS EN EL CONGRESO ANUAL DE ASCO</div>
<div><b>Noticia:</b> <div class=ExternalClass3BECA12EA2DD489F96C6A7D7786A92A8><div></div></div></div>
<div><b>Datos adjuntos:</b> <a href="http://s16117373:11111/Lists/Noticias/Attachments/432/NdP PharmaMar_ASCO_2013_cast_final.pdf">http://s16117373:11111/Lists/Noticias/Attachments/432/NdP PharmaMar_ASCO_2013_cast_final.pdf</a><br><a href=""></a></div>
]]></description>
      <author>S16117373\pharmamar</author>
      <pubDate>Thu, 16 May 2013 12:24:22 GMT</pubDate>
      <guid isPermaLink="true">http://s16117373:11111/Lists/Noticias/DispForm.aspx?ID=432</guid>
    </item>
    <item>
      <title>14/05/2013</title>
      <link>http://s16117373:11111/Lists/Noticias/DispForm.aspx?ID=431</link>
      <description><![CDATA[<div><b>Fecha:</b> 14/05/2013</div>
<div><b>Enlace:</b> PharmaMar completes the Phase Ib trial with PM01183 in combination with Doxorubicin</div>
<div><b>Noticia:</b> <div class=ExternalClass7DD8F5439AAF4F1692946EC7049E1C51><div></div></div></div>
<div><b>Datos adjuntos:</b> <a href="http://s16117373:11111/Lists/Noticias/Attachments/431/PM01183_FI_Doxo_cast_en.pdf">http://s16117373:11111/Lists/Noticias/Attachments/431/PM01183_FI_Doxo_cast_en.pdf</a><br><a href=""></a></div>
]]></description>
      <author>S16117373\pharmamar</author>
      <pubDate>Tue, 14 May 2013 08:25:18 GMT</pubDate>
      <guid isPermaLink="true">http://s16117373:11111/Lists/Noticias/DispForm.aspx?ID=431</guid>
    </item>
    <item>
      <title>14/05/2013</title>
      <link>http://s16117373:11111/Lists/Noticias/DispForm.aspx?ID=430</link>
      <description><![CDATA[<div><b>Fecha:</b> 14/05/2013</div>
<div><b>Enlace:</b> PharmaMar finaliza el estudio de Fase Ib con PM01183 en combinación con Doxorrubicina</div>
<div><b>Noticia:</b> <div class=ExternalClass6B535259EE414415B8797974FFBCE73C><div></div></div></div>
<div><b>Datos adjuntos:</b> <a href="http://s16117373:11111/Lists/Noticias/Attachments/430/PM01183_FI_Doxo_cast.pdf">http://s16117373:11111/Lists/Noticias/Attachments/430/PM01183_FI_Doxo_cast.pdf</a><br><a href=""></a></div>
]]></description>
      <author>S16117373\pharmamar</author>
      <pubDate>Tue, 14 May 2013 08:11:42 GMT</pubDate>
      <guid isPermaLink="true">http://s16117373:11111/Lists/Noticias/DispForm.aspx?ID=430</guid>
    </item>
  </channel>
</rss>